Gut health as a determinant of mitochondrial function

Disruption of this vital interaction contributes to systemic fatigue, heightened inflammation, and the progression of chronic disease, positioning it as a cornerstone of human health.

Few relationships in biology illustrate interdependence more clearly than that between the gut and mitochondria. For years, these two systems were studied separately: the microbiome as a microbial ecosystem, and mitochondria as the energy factories of our cells. Science is now showing how these are tightly linked. The gut determines the quality and quantity of nutrients and metabolites available, while mitochondria determine how efficiently those inputs are converted into cellular energy.

This connection serves as a nutrient-to-energy interface, and when disrupted, it drives dysfunction across multiple organ systems, becoming a significant determinant of both acute and chronic diseases with wide-ranging consequences. Understanding this connection reframes chronic disease as a systems failure rooted in disrupted nutrient processing and energy generation, and it is more than just a research concept. It is emerging as a central framework for understanding energy, resilience, and the origins of chronic disease.

Mitochondria in context

Mitochondria are present in nearly all nucleated cells, with the number of mitochondria proportional to the cell's energy demand. Their abundance reflects energy demand, where muscle cells and neurons contain thousands, and mature red blood cells expel their mitochondria entirely to maximize hemoglobin content. Energy generation is their best-known role, but mitochondria also act as signaling centers, regulate programmed cell death (apoptosis), and integrate nutrient metabolism by oxidizing fatty acids, recycling amino acids, and stabilizing glucose availability. Their ability to function efficiently is contingent upon a healthy gut, which provides both nutrients and regulatory metabolites.

When mitochondria are unhealthy or under stress, it may be felt long before laboratory tests confirm dysfunction. Common symptoms include persistent fatigue, poor stamina, exercise intolerance, muscle weakness or cramping, brain fog, memory issues, headaches, and mood changes. Systemic effects can include blood sugar dysregulation, cold intolerance, unexplained weight changes, and gastrointestinal symptoms such as bloating or poor nutrient absorption. Because mitochondria influence every energy-dependent tissue, dysfunction can also present as cardiovascular complaints (palpitations, exercise-induced discomfort) and heightened inflammatory states (aches, low-grade fevers, immune dysregulation). These nonspecific but cumulative symptoms often represent early signs of impaired mitochondrial performance.

Microbiome influence on mitochondria

The microbiome directly shapes immunity and, through its chemical outputs (metabolites), influences mitochondrial performance. Key beneficial microbes, such as Faecalibacterium prausnitzii, generate butyrate, the primary fuel for our colon cells, which fortifies the intestinal barrier and enhances energy production while mitigating inflammation. Other species contribute acetate and propionate, thereby regulating glucose and lipid metabolism. Meanwhile, Bifidobacterium species support immune tolerance and mucus renewal within the gut lining, which is particularly critical during early life. Akkermansia muciniphila maintains mucus integrity and metabolic balance, whereas expansion of Proteobacteria often signals dysbiosis and endotoxin-driven inflammation.

Microbial fermentation of dietary fiber in the large intestine yields short-chain fatty acids (SCFAs) that not only sustain our gut lining but also optimize mitochondrial efficiency in the liver, skeletal muscle, and brain. Beyond SCFAs, other microbial metabolites, such as bile acids and tryptophan byproducts, act as signaling molecules.

These compounds activate energy-regulating pathways like AMPK (the cell’s energy sensor), PPARs (nuclear receptors that govern fat and glucose metabolism), and FXR (a bile acid receptor that influences mitochondrial stress responses). In doing so, the microbiome fine-tunes how mitochondria balance energy generation, nutrient utilization, and inflammation across tissues. For a deeper dive into the inner workings of our gut microbiome, visit our article on Gut Health and Chronic Disease Part I.

Clinical implications

Communication between the gut and mitochondria relies on a steady flow of immune signals and chemical messages from our microbiomes. These compounds determine whether nutrients are efficiently converted into energy or whether stress and inflammation dominate. The efficiency of mitochondrial energy production depends not only on nutrient intake but also on how those nutrients are processed and delivered by the gut. Microbial metabolites act as key messengers that fine-tune mitochondrial biogenesis, oxidative balance, and nutrient utilization.

When the gut cannot deliver sufficient substrates, the key energy-generating processes (the Krebs cycle and oxidative phosphorylation) falter. Under healthy conditions, mitochondria generate low levels of reactive oxygen species (ROS: chemically reactive byproducts of energy production) that activate antioxidant defenses and promote mitochondrial growth. When systemic inflammation, often triggered by gut permeability or dysfunction, overwhelms this balance, ROS accumulate, the electron transport chain (a chain of proteins that produce energy) becomes impaired, energy declines, and mitochondrial DNA fragments.

The impacts of stressed mitochondria extend across systems. In the cardiovascular system, oxidative stress accelerates gut lining dysfunction and the formation of plaques. In the brain, it contributes to neuronal injury and the progression of Alzheimer’s and Parkinson’s disease. In skeletal muscle, it disrupts insulin signaling and fosters metabolic dysfunction. When mitochondria are impaired or communication fails, energy production drops, oxidative stress rises, and chronic inflammation becomes the prevailing state. All of which are shared hallmarks of metabolic, cardiovascular, neurodegenerative, and immune-mediated diseases.

Measurable markers

Markers of healthy gut-to-mitochondrial communication can be detected through a combination of clinical laboratory tests and advanced functional testing. These tools, when interpreted together, provide a system-level view of how the gut and mitochondria interact in both resilience and disease:

• SCFA levels: stool or plasma analysis for butyrate, acetate, and propionate (e.g. BiomeFx*, GI-MAP* with add-ons).

• Bile acid metabolism: serum or stool bile acid panels, including primary-to-secondary bile acid ratios.

• Tryptophan metabolism: plasma or urine tryptophan-to-kynurenine ratio and indole derivatives, often captured in organic acid testing.

• Organic acid testing (OAT): provides insight into mitochondrial energy output, microbial overgrowth, and nutrient cofactor needs by measuring metabolites in urine.

• Comprehensive stool panels (e.g. GI360*, Gut 360*, GI Effects*): evaluate microbial composition, diversity, inflammation, and fermentation patterns that influence mitochondrial function.

• Circulating mitochondrial DNA (mtDNA): detected in plasma, indicating mitochondrial stress and cellular damage.

• Oxidative stress biomarkers: ratios of reduced-to-oxidized glutathione, F2-isoprostanes, and lipid peroxidation markers.

• Functional mitochondrial testing: high-resolution respirometry measuring ATP output and reserve capacity under stress.

Disease implications

Breakdowns in communication between the gut and mitochondria ripple outward, leading to whole-body dysfunction. The resulting energy deficits, inflammatory cascades, and metabolic disturbances are evident across nearly every domain of chronic disease, influencing how conditions develop and progress.

• Metabolic disorders: Reduced SCFA production weakens mitochondrial energy generation, blunts insulin sensitivity, disrupts blood sugar regulation, and contributes to fatty liver disease

• Cardiovascular system: Microbial byproducts such as trimethylamine N-oxide interfere with the health of blood vessels, making them less flexible and more prone to injury. Mitochondria under stress produce excess reactive oxygen species, which are highly reactive molecules that damage vessel walls and accelerate plaque buildup. Together, these changes raise the risk of heart disease.

• Brain: Mitochondrial stress can be particularly damaging here because mitochondrial respiration (the process of converting nutrients and oxygen into energy) slows down, leaving neurons more fragile. Combined with inflammation triggered by gut permeability, this contributes to the progression of conditions like Parkinson’s and Alzheimer’s disease. In simple terms, when brain cells can’t make enough energy, they struggle to repair themselves and eventually die off.

• Immune system: When fragments of bacteria slip through a weakened gut barrier into the bloodstream, they activate immune defenses. At the same time, stressed mitochondria release reactive oxygen species: chemicals that amplify inflammation. Together, these signals can tip the immune system toward chronic overactivity, increasing the risk of autoimmune conditions.

• Cancer: An unhealthy gut fosters DNA damage and inflammation that support tumor growth. On the contrary, beneficial metabolites like butyrate can help trigger programmed cell death in abnormal cells and support immune defenses against cancer. This duality is tied to the “Warburg effect,” where cancer cells prefer less efficient energy pathways even in oxygen-rich conditions.

Therapeutic and environmental influences

Restoring balance in the connection between our gut and mitochondria requires attention to both targeted therapies and the broader environment in which cells function. Microbiome-directed approaches are among the most promising. Probiotic- and prebiotic-rich foods have been shown to enhance microbial balance, boost short-chain fatty acid production, and reduce systemic inflammation.

Pharmacological agents can also shape this nutrient-to-energy relationship, sometimes beneficially and sometimes with unintended consequences. Metformin, for example, supports mitochondrial oxidative capacity by enhancing the microbiota's ability to produce SCFAs, which helps explain its insulin-sensitizing effects. Statins, widely used to lower cardiovascular risk, alter microbial composition and decrease coenzyme Q10 availability, which may impair mitochondrial respiration in some individuals. Long-term antibiotic use reduces microbial diversity, the production of SCFAs, and disrupts mitochondrial energy metabolism. Certain chemotherapy agents exert direct mitochondrial toxicity, often mediated by their impact on gut microbial communities.

Beyond clinical interventions, environmental and lifestyle factors can shape the resilience of this system. Nutrition remains one of the strongest drivers: diets rich in fiber and plant-based foods encourage the production of microbial metabolites that support mitochondrial biogenesis and efficient energy metabolism, whereas ultra-processed foods blunt these pathways. Physical activity, both endurance and resistance training, enhances microbial diversity, increases the abundance of SCFA-producing bacteria, and stimulates mitochondrial capacity in muscle and other tissues. Sleep and psychological stress also exert powerful influences. Chronic sleep deprivation and ongoing stress weaken the gut barrier, elevate systemic inflammation, and destabilize mitochondrial homeostasis, leaving the body less able to repair and adapt.

Our other microbial ecosystems also contribute to mitochondrial health. Taken together, these therapeutic, environmental, and lifestyle factors suggest that mitochondrial resilience is not determined by a single input, but rather by the ongoing interaction between gut health, systemic microbial communities, and the conditions under which we live.

• The oral microbiome produces inflammatory mediators linked to vascular dysfunction and neurodegeneration. When vascular function is impaired, it contributes to high blood pressure, atherosclerosis, heart disease, stroke, and even cognitive decline.

• The skin microbiome influences immune signaling and oxidative stress. Long-term oxidative stress contributes to inflammation, aging, and chronic diseases such as cardiovascular disease, diabetes, neurodegeneration, and cancer.

• The lung microbiome, when disrupted by infection or pollution, can trigger cytokine-mediated mitochondrial stress in distant organs.

• The vaginal microbiome shapes fertility, pregnancy outcomes, and menopausal health by regulating inflammation and mitochondrial function in reproductive tissues.

• The liver microbiome directly governs hepatocyte mitochondrial metabolism through the gut–liver connection, contributing to the development of fatty liver disease.

• Circadian rhythms, synchronized by daylight, regulate mitochondrial efficiency. Insufficient natural light or excessive artificial light at night disrupts these rhythms, leading to increased oxidative stress.

Supporting this relationship requires careful consideration of interventions, awareness of potential trade-offs, and alignment of daily rhythms with the body’s energy needs. For a deeper understanding of how these microbiomes influence our gut, refer to Gut Health and Chronic Disease Part II.

In conclusion

A disrupted gut-to-mitochondria connection reframes chronic disease as a failure of communication between two essential systems: the microbial networks that process nutrients and the cellular engines that turn them into energy. When this dialogue is intact, the result is efficient metabolism, balanced immunity, and resilience across tissues. When it breaks down, energy falters, inflammation rises, and the pathways of chronic illness accelerate. By recognizing the central role of gut-mitochondria interactions, clinicians and researchers can identify dysfunction earlier, apply targeted testing, and design interventions that restore energy balance at its root. This systems view moves beyond treating symptoms and offers a framework for understanding and addressing the origins of modern chronic disease.

*Disclaimer: The tests and tools mentioned in this article are provided for educational purposes only. We do not endorse any specific laboratory, company, or testing method, nor have we received compensation or sponsorship for including them. Readers should consult with a qualified healthcare professional before pursuing any diagnostic testing or treatment.

References

Borbolis F, Mytilinaiou E, Palikaras K. The Crosstalk between Microbiome and Mitochondrial Homeostasis in Neurodegeneration. Cells. 2023 Jan 28;12(3):429. doi: 10.3390/cells12030429. PMID: 36766772; PMCID: PMC9913973.

Du, Y.; He, C.; An, Y.; Huang, Y.; Zhang, H.; Fu, W.; Wang, M.; Shan, Z.; Xie, J.; Yang, Y.; et al. The Role of Short Chain Fatty Acids in Inflammation and Body Health. Int. J. Mol.Sci.2024,25,7379. https:// doi.org/10.3390/ijms25137379

Front. Pharmacol. 15:1428242. doi: 10.3389/fphar.2024.1428242

Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021 Feb 11;20:301-319. doi: 10.17179/excli2020-3239. PMID: 33746664; PMCID: PMC7975634.

Haque, P.S., Kapur, N., Barrett, T.A. et al. Mitochondrial function and gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 21, 537–555 (2024). https://doi.org/10.1038/s41575-024-00931-2

Kulkarni H, Gaikwad AB. The mitochondria-gut microbiota crosstalk - A novel frontier in cardiovascular diseases. Eur J Pharmacol. 2025 Jul 5;998:177562. doi: 10.1016/j.ejphar.2025.177562. Epub 2025 Mar 27. PMID: 40157703.

Lin, L., Xiang, S., Chen, Y., Liu, Y., Shen, D., Yu, X. ... Ning, Z. (2024). Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review). Experimental and Therapeutic Medicine, 28, 427. https://doi.org/10.3892/etm.2024.12716

Liu X, Xu M, Wang H, Zhu L. Role and Mechanism of Short-Chain Fatty Acids in Skeletal Muscle Homeostasis and Exercise Performance. Nutrients. 2025 Apr 26;17(9):1463. doi: 10.3390/nu17091463. PMID: 40362771; PMCID: PMC12073122.

Loh, J.S., Mak, W.Q., Tan, L.K.S. et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Sig Transduct Target Ther 9, 37 (2024). https://doi.org/10.1038/s41392-024-01743-1

Shanmugham, M.; Bellanger, S.; Leo, C.H. Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics. Pharmaceuticals 2023, 16, 504. https://doi.org/10.3390/ph16040504

Shen, Y., Fan, N., Ma, S.-x., Cheng, X., Yang, X., & Wang, G. (2025). Gut microbiota dysbiosis: Pathogenesis, diseases, prevention, and therapy. Microorganisms, 13(2), 70168. https://doi.org/10.1002/mco2.7016

Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314. https://doi.org/10.1126/science.123.3191.309

Wen L, Yang K, Wang J, Zhou H, Ding W. Gut microbiota-mitochondrial crosstalk in obesity: novel mechanistic insights and therapeutic strategies with traditional Chinese medicine. Front Pharmacol. 2025 Apr 22;16:1574887. doi: 10.3389/fphar.2025.1574887. PMID: 40331200; PMCID: PMC12052897.

Zachos KA, Gamboa JA, Dewji AS, Lee J, Brijbassi S and Andreazza AC (2024), The interplay between mitochondria, the gut microbiome and metabolites and their therapeutic potential in primary mitochondrial disease.

Zhang, D., Jian, YP., Zhang, YN. et al. Short-chain fatty acids in diseases. Cell Commun Signal 21, 212 (2023). https://doi.org/10.1186/s12964-023-01219-9

Zhao H, Qiu X, Wang S, Wang Y, Xie L, Xia X, Li W. Multiple pathways through which the gut microbiota regulates neuronal mitochondria constitute another possible direction for depression. Front Microbiol. 2025 Apr 17;16:1578155. doi: 10.3389/fmicb.2025.1578155. PMID: 40313405; PMCID: PMC12043685.